دورية أكاديمية
أعرض في EDS

Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.

التفاصيل البيبلوغرافية
العنوان: Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.
المؤلفون: Haque A; King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Baig GA; King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Department of Biological Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alshawli AS; King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Sait KHW; Gynecology Oncology Unit, Obstetrics and Gynecology Department, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah 21589, Saudi Arabia., Hafeez BB; Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA., Tripathi MK; Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA., Alghamdi BS; King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Mohammed Ali HSH; Department of Biological Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Rasool M; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
المصدر: Life (Basel, Switzerland) [Life (Basel)] 2022 Mar 07; Vol. 12 (3). Date of Electronic Publication: 2022 Mar 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101580444 Publication Model: Electronic Cited Medium: Print ISSN: 2075-1729 (Print) Linking ISSN: 20751729 NLM ISO Abbreviation: Life (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2011-
مستخلص: Multidrug resistance (MDR) is one of the major therapeutic challenges that limits the efficacy of chemotherapeutic response resulting in poor prognosis of ovarian cancer (OC). The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. We used AutoDock Vina scores to compare the binding affinities of the anticancer drugs against MRP1. Our results depicted Carboplatin < Gemcitabine < Topotecan < Doxorubicin < Paclitaxel as the order of binding affinities. Paclitaxel has shown the highest binding affinity whereas Carboplatin displayed the lowest affinity to MRP1. Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1. Our results suggest that Carboplatin could be an appropriate therapeutic choice against MRP1 in OC as it couples weakly with Carboplatin. Further, our findings also recommend opting Carboplatin with Gemcitabine as a combinatorial chemotherapeutic approach to overcome MDR phenotype associated with recurrent OC.
References: Eur J Pharmacol. 2013 Oct 5;717(1-3):40-6. (PMID: 23660368)
J Clin Oncol. 2015 Sep 10;33(26):2841-7. (PMID: 26240233)
Sci Rep. 2020 Jul 9;10(1):11292. (PMID: 32647151)
Oncology. 2004;66(5):347-52. (PMID: 15331920)
Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41. (PMID: 15839957)
Crit Rev Biotechnol. 2016 Aug;36(4):716-26. (PMID: 25757878)
J Biol Chem. 2002 Feb 15;277(7):5110-9. (PMID: 11741902)
CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280)
Anticancer Res. 2006 May-Jun;26(3B):2227-32. (PMID: 16821592)
Gynecol Oncol. 2003 Aug;90(2 Pt 2):S16-20. (PMID: 12928001)
Biomed Res Int. 2013;2013:143202. (PMID: 24024181)
Bioorg Med Chem. 2011 May 15;19(10):3249-54. (PMID: 21530277)
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489. (PMID: 33237286)
Drug Resist Updat. 2015 Jan;18:1-17. (PMID: 25554624)
Expert Opin Investig Drugs. 2021 May;30(5):543-554. (PMID: 33724122)
Gynecol Oncol. 2004 Dec;95(3):539-45. (PMID: 15581960)
Curr Drug Metab. 2006 Jan;7(1):105-18. (PMID: 16454695)
Front Oncol. 2019 Jun 12;9:487. (PMID: 31245292)
Biochem Pharmacol. 2005 Feb 1;69(3):451-61. (PMID: 15652236)
Eur J Surg Oncol. 2006 Oct;32(8):844-52. (PMID: 16677797)
Biomed Pharmacother. 2011 Aug;65(5):345-53. (PMID: 21775090)
Curr Med Chem. 2011;18(3):439-81. (PMID: 21143116)
Gynecol Oncol. 2010 May;117(2):198-201. (PMID: 19922990)
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:60-70. (PMID: 27894705)
Drug Discov Today. 2017 Feb;22(2):270-281. (PMID: 27890669)
Mol Med Rep. 2015 Nov;12(5):7335-43. (PMID: 26459009)
Gynecol Oncol. 2019 Dec;155(3):530-537. (PMID: 31604664)
Sci Rep. 2018 Aug 10;8(1):11973. (PMID: 30097643)
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W623-33. (PMID: 19498078)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Medicine (Baltimore). 2020 Apr;99(17):e19931. (PMID: 32332673)
Trends Microbiol. 2016 Nov;24(11):862-871. (PMID: 27430191)
Hematol Oncol Clin North Am. 2018 Dec;32(6):903-914. (PMID: 30390764)
J Biol Chem. 2014 Nov 7;289(45):30880-8. (PMID: 25281745)
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. (PMID: 26742998)
Biochim Biophys Acta. 2007 Jun;1775(2):237-62. (PMID: 17572300)
Autophagy. 2015;11(2):225-38. (PMID: 25607466)
Biochim Biophys Acta. 2016 Dec;1866(2):266-275. (PMID: 27717733)
J Cheminform. 2011 Oct 07;3:33. (PMID: 21982300)
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355)
Exp Mol Pathol. 2016 Feb;100(1):139-44. (PMID: 26683819)
Oncol Lett. 2019 Jul;18(1):22-28. (PMID: 31289467)
Ann Oncol. 2006 May;17 Suppl 5:v188-94. (PMID: 16807454)
Clin Breast Cancer. 2004 Jun;5(2):117-22; discussion 123-4. (PMID: 15245614)
J Clin Oncol. 2006 Oct 10;24(29):4699-707. (PMID: 16966687)
معلومات مُعتمدة: 1171 Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia
فهرسة مساهمة: Keywords: carboplatin; gemcitabine; multidrug resistance; multidrug resistance protein 1; ovarian cancer
تواريخ الأحداث: Date Created: 20220325 Latest Revision: 20230308
رمز التحديث: 20230309
مُعرف محوري في PubMed: PMC8954655
DOI: 10.3390/life12030383
PMID: 35330134
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-1729
DOI:10.3390/life12030383